78 related articles for article (PubMed ID: 22891675)
1. Design and characterization of a selenium-containing inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a zinc-containing metalloprotease.
Yoshimoto N; Sasaki T; Sugimoto K; Ishii H; Yamamoto K
J Med Chem; 2012 Sep; 55(17):7696-705. PubMed ID: 22891675
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for inhibition of carboxypeptidase B by selenium-containing inhibitor: selenium coordinates to zinc in enzyme.
Yoshimoto N; Itoh T; Inaba Y; Ishii H; Yamamoto K
J Med Chem; 2013 Oct; 56(19):7527-35. PubMed ID: 24010887
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for the selective inhibition of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) by a selenium-containing inhibitor with chloro-aminopyridine as a basic group.
Itoh T; Yoshimoto N; Hirano Y; Yamamoto K
Bioorg Med Chem Lett; 2018 Jul; 28(13):2256-2260. PubMed ID: 29859906
[TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis.
Vercauteren E; Gils A; Declerck PJ
Semin Thromb Hemost; 2013 Jun; 39(4):365-72. PubMed ID: 23457049
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
[TBL] [Abstract][Full Text] [Related]
6. 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).
Islam I; Bryant J; May K; Mohan R; Yuan S; Kent L; Morser J; Zhao L; Vergona R; White K; Adler M; Whitlow M; Buckman BO
Bioorg Med Chem Lett; 2007 Mar; 17(5):1349-54. PubMed ID: 17189688
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
8. Structures of potent selective peptide mimetics bound to carboxypeptidase B.
Adler M; Buckman B; Bryant J; Chang Z; Chu K; Emayan K; Hrvatin P; Islam I; Morser J; Sukovich D; West C; Yuan S; Whitlow M
Acta Crystallogr D Biol Crystallogr; 2008 Feb; 64(Pt 2):149-57. PubMed ID: 18219114
[TBL] [Abstract][Full Text] [Related]
9. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
10. TAFIa inhibitors in the treatment of thrombosis.
Bunnage ME; Owen DR
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):480-6. PubMed ID: 18600565
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor.
Declerck PJ
Hamostaseologie; 2011 Aug; 31(3):165-6, 168-73. PubMed ID: 21629966
[TBL] [Abstract][Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor activity, thrombin-antithrombin complex and D-dimer levels in preterm neonates with early respiratory distress syndrome.
Gursoy T; Tekinalp G; Yurdakok M; Ozcebe O; Korkmaz A; Gurgey A
Am J Hematol; 2008 Jan; 83(1):50-3. PubMed ID: 17654683
[TBL] [Abstract][Full Text] [Related]
13. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
Neill EK; Stewart RJ; Schneider MM; Nesheim ME
Anal Biochem; 2004 Jul; 330(2):332-41. PubMed ID: 15203340
[TBL] [Abstract][Full Text] [Related]
14. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
15. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R
Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771
[TBL] [Abstract][Full Text] [Related]
16. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
18. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats.
Muto Y; Suzuki K; Iida H; Sakakibara S; Kato E; Itoh F; Kakui N; Ishii H
Crit Care Med; 2009 May; 37(5):1744-9. PubMed ID: 19325462
[TBL] [Abstract][Full Text] [Related]
19. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
Kim PY; Foley J; Hsu G; Kim PY; Nesheim ME
Anal Biochem; 2008 Jan; 372(1):32-40. PubMed ID: 17967438
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa).
Brink M; Dahlén A; Olsson T; Polla M; Svensson T
Bioorg Med Chem; 2014 Apr; 22(7):2261-8. PubMed ID: 24588961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
